RxDoctor Payments Data

Vincent Bonagura, MD

Pediatric Allergy/Immunology · Great Neck, NYNPI 1568556629

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $102,187 of the $137,838 with a category attached, or 74.1%. CSL Behring accounts for 67.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $34,823 and has fallen 68.2% since, to $11,079 in 2025. Among pediatric allergy/immunology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$137,838in general payments, 2019–2025

Across 159 payments — averaging $866.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$93K
  • Shire North American Group Inc$20K
  • Takeda Pharmaceuticals U.S.A., Inc.$16K
  • Grifols USA, LLC$9K
  • Genentech USA, Inc.$41
  • Alk-abello, Inc$15
$157,640in research payments, 2019–2025

Across 81 payments — averaging $1946.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$131K
  • Shire North American Group Inc$18K
  • CSL Behring$8K

What the payments were for

  • Consulting fees$17,67513%
  • Speaking & faculty fees$102,18774%
  • Travel & lodging$14,99111%
  • Food & beverage$2,9852%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$137,838 in reported general payments places this provider in the 95th percentile of 51 pediatric allergy/immunology providers in New York.

See all pediatric allergy/immunology providers in New York

Medicare billing

Part B allowed, 2024
$14,358
Medicare patients
39
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5031$76,542
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5024$53,256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$92,749$76,54231 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$15,880$53,25624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 51 pediatric allergy/immunology providers in New York.

Other pediatric allergy/immunology in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →